Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
| Autor: | Garcia, Christine, Abrahami, Devin, Polli, Anna, Chu, Haitao, Chandler, Conor, Tan, Min, Kelton, John Mark, Thomaidou, Despina, Bauer, Todd |
|---|---|
| Zdroj: | In Clinical Lung Cancer November 2024 25(7):634-642 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect